Monthly Archives: April 2015

Home/2015/April

Blueprint Medicines Presents Preclinical Data on BLU-285

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]

By |2019-04-08T10:13:47-04:00April 24th, 2015|D842V, News, Research|

Fatigue Reduction: Moving Towards a Better Future

As one of the most common side-effects of Gleevec, Sutent and Stivarga, fatigue is a condition that many GIST survivors are intimately acquainted with. The National Comprehensive Cancer Network defines cancer-related fatigue as “a [...]

By |2019-07-03T11:09:18-04:00April 7th, 2015|News, Side Effects|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|
Go to Top